Mirum Pharmaceuticals (FRA:08D) Buildings And Improvements : €0.0 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals Buildings And Improvements?

Mirum Pharmaceuticals's quarterly buildings and improvements increased from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€1.2 Mil) but then declined from Dec. 2023 (€1.2 Mil) to Mar. 2024 (€0.0 Mil).

Mirum Pharmaceuticals's annual buildings and improvements declined from Dec. 2021 (€1.4 Mil) to Dec. 2022 (€1.4 Mil) and declined from Dec. 2022 (€1.4 Mil) to Dec. 2023 (€1.2 Mil).

Mirum Pharmaceuticals Buildings And Improvements Historical Data

The historical data trend for Mirum Pharmaceuticals's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Buildings And Improvements Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

1.39

1.35

1.18

Mirum Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	1.18	-

Mirum Pharmaceuticals Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Mirum Pharmaceuticals (FRA:08D) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

MIRM:USA MIRM:Mexico

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals (FRA:08D) Headlines

No Headlines